Syntara Limited

SNT

AU0000312480

Pharmaceuticals

End-of-day quote Australian S.E. Other stock markets 03:30:00 09/05/2024 am IST			5-day change	1st Jan Change
0.016 ^AUD	-11.11%		-5.88%	-20.00%

30/04	Transcript : Syntara Limited, Q3 2024 Earnings Call, Apr 30, 2024
10/04	Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment	MT

Pharmaxis to accelerate plans for myelofibrosis combination study after FDA talks

April 13, 2023 at 02:01 am IST

(via NewsDirect)

Pharmaxis Ltd (ASX:PXS) CEO Gary Phillips tells Proactive the company will add a combination treatment arm to the current Phase 2 clinical trial of PXS‐5505 in myelofibrosis following helpful feedback from the US FDA. He says they’re already in discussion with the existing trial site investigators who have welcomed the opportunity to extend the patient population for the study and anticipate significantly accelerated recruitment.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

Latest news about Syntara Limited

Transcript : Syntara Limited, Q3 2024 Earnings Call, Apr 30, 2024	30/04
Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment	10/04	MT
Syntara Limited Reports Earnings Results for the Half Year Ended December 31, 2023	29/02	CI
Syntara to Begin Phase Two Study for SNT-5505 Combination Therapy Later in 2024 After Government Grant	14/02	MT
Transcript : Syntara Limited - Shareholder/Analyst Call	31/01
Syntara Opens Up to AU$2 Million Share Purchase Plan	29/12	MT
Syntara Starts Dosing Patients in Phase Two Trial of Drug Candidate	13/12	MT
Syntara Receives AU$5.2 Million R&D Tax Rebate	05/12	MT
Pharmaxis Doses First Patient in Phase Two Sleep Trial	10/11	MT
Pharmaxis Ltd Reports Earnings Results for the First Quarter Ended September 30, 2023	31/23/31	CI
Transcript : Pharmaxis Ltd, Q1 2024 Earnings Call, Oct 31, 2023	31/23/31
Pharmaxis Sells Mannitol Business; Shares Fall 3%	19/23/19	MT
Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis.	19/23/19	CI
BTC Health Arm to Continue Distributing Bronchitol, Aridol in Australia	04/23/04	MT
Pharmaxis to Change Name Amid Restructure, Appoints Chair	03/23/03	MT
Transcript : Pharmaxis Ltd - Special Call	03/23/03
Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis.	03/23/03	CI
Australian Bourse Halts Trading in Pharmaxis’ Securities	02/23/02	MT
Pharmaxis Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	28/23/28	CI
Pharmaxis Secures $4 Million R&D Loan	08/23/08	MT
Transcript : Pharmaxis Ltd, Q4 2023 Earnings Call, Jul 31, 2023	31/23/31
Pharmaxis Logs Positive Results in Cancer Trial	13/23/13	MT
Transcript : Pharmaxis Ltd - Special Call	12/23/12
Transcript : Pharmaxis Ltd - Special Call	24/23/24
Pharmaxis Shares Temporarily Halt Trading on ASX	22/23/22	MT

Chart Syntara Limited

Duration

Period

More charts

Company Profile

Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Companyâs highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinsonâs by reducing neuroinflammation. The Companyâs other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. It has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.

Sector

Pharmaceuticals

Calendar

14/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Syntara Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SYNTARA LIMITED	-20.00%	14.13M
ELI LILLY AND COMPANY	+32.36%	698B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.40%	358B
MERCK & CO., INC.	+19.46%	328B
ABBVIE INC.	+3.50%	283B
ASTRAZENECA PLC	+16.34%	238B
NOVARTIS AG	+6.68%	203B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+8.62%	165B

Other Pharmaceuticals

Syntara Limited

Equities

SNT

AU0000312480

Pharmaceuticals

Pharmaxis to accelerate plans for myelofibrosis combination study after FDA talks

Contact Details

Latest news about Syntara Limited

Chart Syntara Limited

Company Profile

Income Statement Evolution

Ratings for Syntara Limited

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals